2-氨基-5-氯苯硼酸频那醇酯 | 1073371-77-3

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸/亚磺酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-氯苯硼酸频那醇酯
• 中文别名: 2-氨基-5-氯苯硼酸频呐醇酯
• 英文名称: 4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
• 英文别名: 2-amino-5-chlorophenylboronic acid pinacol ester；4-chloro-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)aniline；4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine
• CAS: 1073371-77-3
• 化学式: C₁₂H₁₇BClNO₂
• 分子量: 253.536
• InChiKey: GVJZHGCVSYBPIM-UHFFFAOYSA-N

物化性质

• 沸点：
  371.2±32.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Amino-5-Chlorophenylboronic Acid Pinacol Ester
: BML00099
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 253,54 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Amino-5-Chlorophenylboronic Acid Pinacol Ester
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Amino-5-Chlorophenylboronic Acid Pinacol Ester
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-氯苯硼酸频那醇酯 在 barium hydroxide octahydrate 、 溶剂黄146 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.0h， 生成 2-(2-azido-5-chlorophenyl)pyridine
  参考文献：
  名称：

  RhII2催化芳基叠氮化物合成α-、β-或δ-咔啉

  摘要：

  接近所有异构体：使用羧酸铑 (II) 催化剂可从邻位取代芳基叠氮化物中轻松获得一系列 α-、β- 和 δ-咔啉鎓离子（参见方案）。咔啉离子很容易被还原以提供色氨酸或去质子化以获取吡啶并吲哚。这种 [Rh II 2 ]-催化的 C  H 键胺化用于合成 (±)-horsfiline 和新隐碱。esp=α,α,α',α'-四甲基-1,3-苯二丙酸酯。

  DOI：

  10.1002/anie.201201788
• 作为产物：
  描述：

  对氯苯胺 在 甲醇 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 3,4,7,8-四甲基-1,10-菲罗啉 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 2-氨基-5-氯苯硼酸频那醇酯
  参考文献：
  名称：

  C?H 硼化的无痕导向组

  摘要：

  无痕：氮杂环或苯胺中氮的硼酸化为随后的催化 C  H 硼酸化提供了一个无痕导向基团。可以实现以前需要 Boc 保护的选择性；此外，NBpin导向基团可以原位安装和拆卸，产品收率显着提高。Boc=叔丁氧基羰基，pin=频哪醇。

  DOI：

  10.1002/anie.201306511

文献信息

• PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Sichuan Haisco Pharmaceutical Co., Ltd.

  公开号：US20170029423A1

  公开（公告）日：2017-02-02

  Provided is a pyridone or pyrimidone derivative(s) represented by general formula (I) and its preparation method and use. Substituents of the compound of general formula (I) are defined the same as in the specification.

  提供的是由一般式（I）表示的吡啶酮或嘧啶酮衍生物，以及其制备方法和用途。一般式（I）化合物的取代基的定义与规范中相同。
• Oxidation of Nonactivated Anilines to Generate <i>N</i>-Aryl Nitrenoids
  作者：Tianning Deng、Wrickban Mazumdar、Russell L. Ford、Navendu Jana、Ragda Izar、Donald J. Wink、Tom G. Driver

  DOI：10.1021/jacs.9b13599

  日期：2020.3.4

  and selective C-NAr and C-C bond formation to yield spirocyclic- or bicyclic 3H-indoles or benzazepinones. Our experiments demonstrate the breadth of these oxidative processes, uncover underlying fundamental elements that control selectivity and demonstrate how the distinct reactivi-ty patterns embedded in N-aryl nitrenoid reactive intermediates can enable access to functionalized 3H-indoles or benzazepinones

  已开发出 2-取代苯胺的低温无保护基氧化以生成亲电 N-芳基氮烯中间体，该中间体可以参与 C-NAr 键的形成以构建功能化的 N-杂环。将 2-取代苯胺暴露于 PIFA 和三氟乙酸或 10 mol% 的 Sc(OTf)3 会触发类氮烯类化合物的形成，然后形成生产性和选择性的 C-NAr 和 CC 键，以产生螺环或双环 3H-吲哚或苯并氮杂酮。我们的实验证明了这些氧化过程的广度，揭示了控制选择性的潜在基本要素，并证明了嵌入在 N-芳基氮烯类反应中间体中的独特反应模式如何能够获得功能化的 3H-吲哚或苯并氮杂酮。
• I(III)-Catalyzed Oxidative Cyclization–Migration Tandem Reactions of Unactivated Anilines
  作者：Tianning Deng、Emily Shi、Elana Thomas、Tom G. Driver

  DOI：10.1021/acs.orglett.0c03497

  日期：2020.11.20

  An I(III)-catalyzed oxidative cyclization–migration tandem reaction using Selectfluor as the oxidant was developed that converts unactivated anilines into 3H-indoles is reported herein. The reaction requires as little as 1 mol % of the iodocatalyst and is mild, tolerating pyridine and thiophene functional groups, and the dependence of the diastereoselectivity of the process on the identity of the iodoarene

  本文报道了使用 Selectfluor 作为氧化剂的 I(III) 催化氧化环化-迁移串联反应，将未活化的苯胺转化为 3 H-吲哚。该反应只需要 1 mol% 的碘催化剂，并且是温和的，可耐受吡啶和噻吩官能团，并且该过程的非对映选择性依赖于碘芳烃或碘代烷烃预催化剂的特性表明该催化剂存在于立体化学反应中。确定 C-N 键形成步骤。
• [EN] DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES DIAMIDES UTILISÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016205482A1

  公开（公告）日：2016-12-22

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Nano-cuprous oxide catalyzed one-pot synthesis of a carbazole-based STAT3 inhibitor: a facile approach via intramolecular C–N bond formation reactions
  作者：C. P. Baburajeev、Chakrabhavi Dhananjaya Mohan、Govindagouda S. Patil、Shobith Rangappa、Vijay Pandey、Anusha Sebastian、Julian E. Fuchs、Andreas Bender、Peter E. Lobie、Basappa Basappa、Kanchugarakoppal S. Rangappa

  DOI：10.1039/c6ra01906d

  日期：——

  In this study, we report the one-pot synthesis of substituted carbazole derivatives using nano cuprous oxide as a catalyst via intramolecular C–N bond forming reactions. Among the synthesized carbazoles, 3′-((3-acetyl-6-chloro-9H-carbazol-9-yl)methyl)-[1,1′-biphenyl]-2-carbonitrile (ACB) was identified as a lead antiproliferative agent against lung cancer cell lines A549 and LLC with an IC50 of 13

  在这项研究中，我们报告了通过分子内C–N键形成反应使用纳米氧化亚铜作为催化剂的一锅法合成取代咔唑衍生物。在合成的咔唑中，3'-（（（3-乙酰基-6-氯-9 H-咔唑-9-基）甲基）-[1,1'-联苯] -2-腈（ACB）被鉴定为铅具有IC 50的抗肺癌细胞A549和LLC的抗增殖药分别为13.6和16.4μM。此外，我们发现该铅化合物抑制了A549，HCC-2279和H1975细胞中STAT3（Tyr-705）的组成型磷酸化。我们分析了ACB处理的HCC-2279细胞的核提取物中磷酸化STAT3和LSD1的水平，以评估STAT3的转录活性。我们发现磷酸化STAT3的下调在LSD1的表达中没有任何变化，表明ACB下调了STAT3的转录活性。分子对接分析表明，ACB与STAT3的SH2结构域的pTyr位点上的Arg-609和Ser-613具有良好的相互作用。